English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

OBJECTIVES: In this prospective phase II clinical study we analyzed whether dynamic contrast enhanced (DCE) MRI is able to distinguish between anti-vascular and anti-tumor effects in the course of anti-angiogenic treatment of recurrent high-grade glioma patients (rHGG). METHODS: Twenty-two patients with rHGG (16 glioblastoma, 5 anaplastic astrocytoma, 1 anaplastic oligoastrocytoma) were treated biweekly with bevacizumab/irinotecan. DCE-MRI scans were performed prior to (baseline) and eight weeks after treatment commencement. DCE-MRI analysis included four semiquantitative parameters, describing gadolinium contrast medium behavior: 1) initial slope of signal increase (marker for vessel permeability; slope), 2) maximum enhancement (marker for extravascular volume; ME), 3) time from starting of curve increase until ME (time-to-peak; TTP), 4) area under the curve until ME (AUC). Comparison of DCE parameters at baseline and follow-up was performed by Wilcoxon rank test. Responders to anti-angiogenic therapy were defined as having a progression free survival greater than 6 months. RESULTS: Mean PFS was 4.0 ± 2.2 months and 4 patients had a PFS greater than 6 months. At baseline there was no difference in ME, TTP, AUC and slope between responder and non-responder. At follow-up responders showed a significant decrease in ME, TTP and AUC, whereas slope did not change (mean ME 60.03% vs. 23.00%, mean TTP 579.5sec vs 367.4sec, mean AUC 55040 vs 12150, p < 0.001, respectively, slope 1.03 vs 1.04). In contrary, non-responder showed no change in ME, TTP and AUC but an increase in slope (mean ME 55.45% vs. 50.21%, mean TTP 539.0sec vs. 523.4sec, mean AUC 53440 vs. 50320 and slope 1.49 vs 1.74, p < 0.001). CONCLUSION: Semiquantitative DCE-MRI analysis may identify responders to anti-angiogenic therapy characterized by a significant decrease in extravascular volume despite lack of reduction in vascular permeability. These results may provide insights into anti-angiogenic treatment effects and serve as a new imaging biomarker in rHGG patients undergoing bevacizumab therapy.

O7.04 * DCE-MRI DISCRIMINATES BETWEEN RESPONDER AND NON-RESPONDER IN RECURRENT HIGH-GRADE GLIOMA PATIENTS UNDERGOING ANTI-ANGIOGENIC TREATMENT